Siegfried Opens New Drug Substances R&D Center in Evionnaz
Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried inaugurated its new global research and development (R&D) center for drug substances at its site in Evionnaz, Switzerland. The 4,500 m2 center houses chemical and analytical facilities, laboratories, and technologies such as flow chemistry, advanced distillation and process analytical technology, as well as new office space.
Together with the R&D center in Zofingen, it will offer chemical process R&D and analytical development services for Siegfried's global drug substances network. With workspaces for over 100 specialists and 40 new jobs created, the R&D center strengthens Siegfried’s development capabilities in phase II and III supporting the company's Evolve+ strategy, the company said.
Marcel Imwinkelried, CEO of Siegfried, commented: “The new R&D Center in Evionnaz significantly enhances our Drug Substances network and demonstrates our unwavering commitment to providing cutting-edge research and development capabilities for our customers. It will be a key element in driving development excellence as part of our Evolve+ strategy and represents another pivotal step in strengthening our position among the top providers in the CDMO sector."
